Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Anti–Factor Xa Assay—A Changing Standard for Venous Thromboprophylaxis?

Anti–Factor Xa Assay—A Changing Standard for Venous Thromboprophylaxis? Research Original Investigation Anti–Factor Xa Trough Level–Adjusted Enoxaparin and Venous Thromboembolism Invited Commentary Anti–Factor Xa Assay—A Changing Standard for Venous Thromboprophylaxis? Kristin Cook, MD; Massimo Napolitano, MD; Frank T. Padberg Jr, MD Venous thromboembolism (VTE) represents a significant Management of infrapopliteal DVT remains controversial, public health concern and is the leading cause of prevent- especially as a surrogate for pulmonary embolism. able deaths in hospitalized patients. The Agency for Health- Given the price of the assay, the cost-effectiveness of test- care Research and Quality ing prophylactic doses of enoxaparin sodium remains an is- has identified this topic as sue. With greater use, the cost has decreased to $25 per assay Related article page 1006 a top 10 public safety con- from the $41 quoted by Ko and colleagues. Identifying pa- cern to be addressed. As with other VTE investigations, tients at higher risk, such as those with elevated creatinine lower extremity deep vein thrombosis (DVT) serves as a sur- clearance, will be useful in guiding future investigations. rogate for fatal pulmonary embolism. Dose adjustment is conventionally monitored by mea- Trauma patients are a uniquely vulnerable population. suring peak anti-Xa levels. However, these investigators Low-molecular-weight heparin at a standard dosage http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Surgery American Medical Association

Anti–Factor Xa Assay—A Changing Standard for Venous Thromboprophylaxis?

JAMA Surgery , Volume 151 (11) – Nov 6, 2016

Anti–Factor Xa Assay—A Changing Standard for Venous Thromboprophylaxis?

Abstract

Research Original Investigation Anti–Factor Xa Trough Level–Adjusted Enoxaparin and Venous Thromboembolism Invited Commentary Anti–Factor Xa Assay—A Changing Standard for Venous Thromboprophylaxis? Kristin Cook, MD; Massimo Napolitano, MD; Frank T. Padberg Jr, MD Venous thromboembolism (VTE) represents a significant Management of infrapopliteal DVT remains controversial, public health concern and is the leading cause of prevent- especially as a surrogate for pulmonary...
Loading next page...
 
/lp/american-medical-association/anti-factor-xa-assay-a-changing-standard-for-venous-thromboprophylaxis-tgFNfSVbVH
Publisher
American Medical Association
Copyright
Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6254
eISSN
2168-6262
DOI
10.1001/jamasurg.2016.1851
pmid
27383470
Publisher site
See Article on Publisher Site

Abstract

Research Original Investigation Anti–Factor Xa Trough Level–Adjusted Enoxaparin and Venous Thromboembolism Invited Commentary Anti–Factor Xa Assay—A Changing Standard for Venous Thromboprophylaxis? Kristin Cook, MD; Massimo Napolitano, MD; Frank T. Padberg Jr, MD Venous thromboembolism (VTE) represents a significant Management of infrapopliteal DVT remains controversial, public health concern and is the leading cause of prevent- especially as a surrogate for pulmonary embolism. able deaths in hospitalized patients. The Agency for Health- Given the price of the assay, the cost-effectiveness of test- care Research and Quality ing prophylactic doses of enoxaparin sodium remains an is- has identified this topic as sue. With greater use, the cost has decreased to $25 per assay Related article page 1006 a top 10 public safety con- from the $41 quoted by Ko and colleagues. Identifying pa- cern to be addressed. As with other VTE investigations, tients at higher risk, such as those with elevated creatinine lower extremity deep vein thrombosis (DVT) serves as a sur- clearance, will be useful in guiding future investigations. rogate for fatal pulmonary embolism. Dose adjustment is conventionally monitored by mea- Trauma patients are a uniquely vulnerable population. suring peak anti-Xa levels. However, these investigators Low-molecular-weight heparin at a standard dosage

Journal

JAMA SurgeryAmerican Medical Association

Published: Nov 6, 2016

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month